Skip to main content
Fig. 2 | Cancer Cell International

Fig. 2

From: ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy

Fig. 2

ATP1A1-4 expression in melanoma cell lines. A Evaluation of transcriptome profiling in 11 melanoma cell lines, focusing on ATP1A1 in relation with the Verfaillie proliferative/Invasive gene signatures. B Fold change between the ATP1A1 mRNA level in resistant cells and in their sensitive counterparts obtained by qPCR. C Fold change between the ATP1A1 protein level in resistant cells and in their sensitive counterparts obtained by Western blot. D ATP1A1 was the most expressed isoform in both sensitive and resistant MM074 and HBL cells, comparing the 4 isoforms (1–4); MM161 and MM161-R lines expressed lower levels of ATP1A1 and had also a higher level of ATP1A3. Data B-D are presented in mean + SD, ANOVA and Tukey post-hoc test

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us